Business
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising.
About this update from Insilico Medicine Cayman Topco
[{"type":"text","content":"HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising.","length":517,"tagName":"p"},{"type":"image","alt":"Insilico Medicine","displaySize":"","headline":null,"caption":"Insilico Medicine","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/27509aeca46965f43144a283ed48ebe0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/u7ZdlG0u_hToMtk5Sk0uMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/27509aeca46965f43144a283ed48ebe0","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2852797/Insilico_IPO.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""With this massively oversubscribed listing we set several world's firsts further confirming Insilico's validated leadership position in AI-powered drug discovery and development and the strength of our platform and pipeline. Insilico is dedicated to extending human productive longevity and this listing provides us with more resources to advance our mission", says Alex Zhavoronkov, PhD, Founder and CEO, Chief Business Officer of Insilico Medicine. "Over the past few years, we set very clear industry benchmarks demonstrating that AI can help make drug discovery faster, cheaper, and deliver higher success rates in preclinical and early clinical development. We have validated the end-to-end capabilities of AI-empowered programs from novel target discovery to molecular generation, and then to preclinical and clinical stages. Going forward, we will continue to increase investment in our AI platform and innovative pipeline, accelerate the advancement of differentiated innovative programs into clinic, and bring truly accessible, affordable, and breakthrough treatment solutions to patients worldwide."","length":1138,"tagName":"p"},{"type":"text","...